key: cord-0978392-tlsuw3ag
authors: Mady, Ahmed; Aletreby, Waleed; Abdulrahman, Basheer; Lhmdi, Mohammed; Noor, Alfateh; Alqahtani, Saleh A.; Soliman, Ibrahim; Alharthy, Abdulrahman; Karakitsos, Dimitrios; Memish, Ziad A.
title: Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case series
date: 2020-11-05
journal: Ann Med Surg (Lond)
DOI: 10.1016/j.amsu.2020.10.061
sha: b7c4bbcee7c2ce004527001f6ad79560e25b2b0e
doc_id: 978392
cord_uid: tlsuw3ag

BACKGROUND: COVID-19 associated critical illness characterized by rapidly evolving acute respiratory failure (ARF) can develop, especially on the grounds of hyperinflammation. AIM AND METHODS: A case-series of 61 patients admitted to our intensive care unit (ICU) between August 12 and September 12, 2020 with confirmed COVID-19 pneumonia and rapidly evolving ARF requiring oxygen support therapy and/or mechanical ventilation was retrospectively analyzed. We examined whether intravenous administration of tocilizumab, a monoclonal interleukin-6 receptor antibody, was associated with improved outcome. All patients received empiric antivirals, dexamethasone 6 mg/day for 7 days, antibiotics, and prophylactic anticoagulation. Tocilizumab was administered at a dosage of 8 mg/kg [two consecutive intravenous infusions 12 h apart]. Outcome measures such as mortality on day-14, ICU length of stay, and rate of nosocomial acquired bacterial infections were also analyzed. Results: Patients were males (88.2%) aged 51 [interquartile range (IQR): 42.5–58.75)], with admission Acute Physiology and Chronic Health Evaluation (APACHE) 4 score of 53 (IQR: 37.75–72.5), and had more than one comorbidity (62.3%). On admission, twenty nine patients (47.5%) were mechanically ventilated, and thirty two patients (52.5%) were receiving oxygen therapy. No serious adverse effects due to tocilizumab therapy were recorded. However, twelve patients (19.6%) developed nosocomial acquired infections. ICU length of stay was 13 (IQR: 9–17) days, and mortality on day-14 was 24.6%. Six patients were shifted to other hospitals but were followed-up. The overall mortality on day-30 was 31.1%. Non-mechanically ventilated patients had higher survival rates compared to mechanically ventilated patients although results were not significant [hazards ratio = 2.6 (95% confidence intervals: 0.9–7.7), p = 0.08]. Tocilizumab did not affect the mortality of critically ill COVID-19 patients. CONCLUSION: Tocilizumab could be an adjunct safe therapy in rapidly evolving COVID-19 pneumonia and associated critical illness.

days, and mortality on day-14 was 24.6%. Six patients were shifted to other hospitals but were followed-up. The overall mortality on day-30 was 31.1%. Non-mechanically ventilated patients had higher survival rates compared to mechanically ventilated patients although results were not significant [hazards ratio = 2.6 (95% confidence intervals: 0.9 -7.7), p = 0.08]. Tocilizumab did not affect the mortality of critically ill COVID-19 patients.

Tocilizumab could be an adjunct safe therapy in rapidly evolving COVID-19 pneumonia and associated critical illness.

Keywords: COVID-19 pneumonia, tocilizumab, acute respiratory failure, mechanical ventilation.

Coronaviruses are enveloped RNA viruses of zoonotic pathogenicity that can cause severe respiratory disorders such as the Middle East Respiratory Syndrome (MERS) and the Severe Acute Respiratory Syndrome (SARS-CoV) [1, 2] . The novel SARS-CoV-2 disease (COVID- 19) emerged from China, in 2019, and spread worldwide [3, 4] . COVID-19 was declared a pandemic by the World Health Organization (WHO) on March 11, 2020 [5] . To date, more than 41.550.000 infected cases were reported, while the death toll reached to 1.137.332 patients worldwide [6] . The clinical presentation of COVID-19 ranged from asymptomatic cases to critical illness requiring intensive care unit (ICU) admission [3, 4, 7, 8] . Most COVID-19 cases were mild necessitating only minimal oxygen support during the acute phase of hospitalization [9] . COVID-19 associated critical illness was characterized by acute respiratory failure, sepsislike features, thromboembolic disease, extra-pulmonary manifestations and multi-system organ failure [3, 4, 7, 8] .

Although the underlying pathophysiology of COVID-19 is extremely versatile [10, 11] , previous studies reported that critically ill patients had higher plasma concentrations of proinflammatory cytokines such as interleukin (IL)-6, IL-10, granulocyte colony stimulating factor, tumor necrosis factor amongst others [12] . Post-mortem lung tissue histopathology examinations revealed variable degrees of alveolar edema, proteinaceous exudate, inflammatory cellular infiltration, and microthrombosis [13] [14] [15] . Apart from the established role of COVID-19 associated severe thromboembolic disease [16] [17] [18] , other cofactors such as dysregulated host immune response, and hyperinflammation could enhance the development of lung tissue damage and ensuing fibrosis [19, 20] . However, only a subgroup of COVID-19 patient develops fulminant respiratory J o u r n a l P r e -p r o o f failure for reasons that remain obscure. The optimal management of these cases is an on-going challenge. IL-6 is a pivotal inflammatory mediator in the development of COVID-19 associated hyperinflammation; however, increased levels of other routine laboratory parameters such as Creactive protein (C-RP), lactate dehydrogenase, ferritin, and D-dimers along with persistent lymphocytopenia were reported in COVID-19 patients with rapidly evolving respiratory failure [6] [7] [8] [9] [10] [11] [12] . Tocilizumab (TCZ), which is a recombinant, humanized monoclonal antibody against both soluble and membrane bound IL-6 receptors, was suggested to mitigate the COVID-19 associated cytokine storm [21] [22] [23] , and was used in the management of severe COVID-19 but with variable clinical results [24, 25] . In this retrospective, single center study, we present the clinical features of COVID-19 critically ill patients who underwent therapy with TCZ, and outline their course and outcome.

We retrospectively analyzed patients with severe COVID-19 who were admitted to our level III 300 bed ICU (King Saud Medical City, Riyadh, Saudi Arabia) between August 12 and September 12, 2020. Inclusion criteria were [26] : 1) Adult ≥ 18 years old, 2) ICU admission with at least one of the following indications: a) mechanical ventilation, b) respiratory rate > 30 b/min, c) peripheral oxygen saturation (SpO 2 ) < 90% on room air, d) SpO 2 to fraction of inspired oxygen ratio (FiO 2 ) < 300, and 3) administration of tocilizumab. SARS-CoV-2 infection was confirmed by Real-Time-Polymerase-Chain-Reaction (RT-PCR) assays according to WHO recommendations [27] , and using QuantiNova Probe RT-PCR kit (Qiagen) in a Light-Cycler 480 real-time PCR system (Roche, Basel, Switzerland) [28] . Exclusion criteria were: 1) pregnancy, 2) known immune suppression/deficiency status, 3) specific contraindications for the use of TCZ including suspected or confirmed bacterial infection, active diverticulitis or gastrointestinal tract J o u r n a l P r e -p r o o f perforation, neutropenia (0.500 × 10 3 cells/uL) and thrombocytopenia (50 × 10 3 cells/uL), and 3) two consecutive negative RT-PCR tests for SARS-CoV-2 taken at least 48 hours apart. Our aim was to analyze the clinical course of critically ill COVID-19 patients who received TCZ.

Outcome measures such as 14-day ICU survival, tocilizumab side-effects, and subgroup analysis between mechanically ventilated and non-mechanically ventilated COVID-19 patients were also reported.

All enrolled patients were treated with empiric antiviral medications (lopinavir 400 mg + ritonavir 100 mg or ribavirin 400 mg every 12 hours for 14 days), antibiotic prophylaxis 

Continuous variables are presented as medians with interquartile range (IQR), whereas categorical variables as numbers and/or percentages. Each variable was presented with its corresponding 95% confidence interval (CI). Subgroup analysis between mechanically ventilated and non-mechanically ventilated COVID-19 patients was performed by the student's t-test or the Wilcoxon rank sum test for continuous variables, and by the chi square test or the Fisher's exact test for categorical variables, as appropriate. Also, we tailored a cox proportional hazard model to compare the hazard of 14-day mortality in the aforementioned subgroups of patients. Results were presented as hazard ratio with log rank p value, and visually displayed as Kaplan Meier curve. The proportional hazard model was adjusted for all variables found to have significant difference in subgroup comparison, or deemed of clinical importance, and we used an enter method retaining variables with p value < 0.1. All statistical tests were two tailed, and considered significant with p value < 5%. Commercially available statistical package Stata® was used for 

Out of the eighty two patients that were admitted to our unit during the study period, sixty one consecutive COVID-19 patients fulfilled the inclusion criteria. The baseline characteristics of these sixty one patients who received TCZ are presented in Table 1 (Table 1 ). The majority of patients (62.3%) had more than one comorbidity. Usual comorbidities were diabetes mellitus (39.3%), arterial hypertension (21.7%), and obesity (24.6%). Upon inclusion, patients had lymphocytopenia and increased C-RP, and Ddimers. The prevalence of pulmonary embolism (PE) confirmed by computed chest tomography angiography was 11.4% in this series (Table 1 ). There were no cases of acute kidney injury necessitating continuous renal replacement therapy in this cohort. Also, no cardiovascular complications were observed during the study period. Upon admission, twenty nine patients (47.5%) were mechanically ventilated, and thirty two patients (52.5%) were non-mechanically ventilated but received oxygen support therapies [HFNC: twenty cases, H-CPAP: eight cases and Venturi mask: four cases]. ICU length of stay was 13 (IQR: 9 -17) days, and hospital length of stay was 14 (IQR: 9 -21) days. Acinetobacter baumannii]. UTI due to Acinetobacter baumannii was recorded in one case. TCZ therapy was not discontinued due to these infections as no episodes of septic shock or other serious adverse effects were documented. Moreover, these infections were not correlated with mortality.

The clinical course of the sixty one COVID-19 patients who underwent TCZ therapy is illustrated in the charted Table 2 Subgroup analysis of mechanically ventilated versus non-mechanically ventilated patients revealed that the former had significantly higher body mass index and rate of hospital acquired infections, and increased ICU/hospital length of stay compared to the latter (Table 3) 

The results of this retrospective, open-label, single-arm, single-center study can be summarized as follows. Unlike other similar studies from the Middle East region [21] , our cohort consisted mainly of Asian males with a median age of 51 years old. Our reported mortality rates of 24.6% (on day-14 post-ICU admission) and 31.1% (on day-30 integrating patients that were shifted to other hospitals) are comparable with recently published studies [36]. Lower mortality rates ranging from 7% to 12% were previously reported by other authors, although the percentage of non-mechanically ventilated and presumably less critically ill patients enrolled in these studies was significantly higher [21, 37] . In contrast, a large multicenter study integrating a longer follow-up period reported mortality rates post TCZ therapy up to 49%, which is in accordance with our findings [38] . Several cofounders such as comorbidities, thromboembolic disease, and J o u r n a l P r e -p r o o f mechanical ventilation affect mortality in COVID-19 studies [3, 4, 7, 8] . The incidence of PE in our series was relatively low; however all patients received prophylactic anticoagulation based on a standardized protocol [16] [17] [18] . Also, the majority of our patients suffered from more than one comorbidity with diabetes mellitus and arterial hypertension being the most commonly observed [3, 4] . We failed to show any differences in mortality between mechanically ventilated versus non-mechanically ventilated patients [3, 4, 7, 8] but our retrospective study was significantly underpowered. However, subgroup analysis revealed higher body mass index and rate of nosocomial acquired infections in the COVID-19 mechanically ventilated subgroup of patients versus the non-mechanically ventilated group, which is in accordance with previous reports [39] [40] [41] [42] [43] [44] [45] [46] [47] . In our study, the incidence of nosocomial acquired infections based on strict clinical criteria was 19.6%, which although an important cofactor did not affect mortality during TCZ therapy. Other studies reported rates of positive cultures from various sites up to 54% during TCZ treatment although nosocomial acquired infections were not clearly defined and/or evaluated [47] . Surely, the immunomodulatory effect of TCZ, especially in mechanically ventilated patients, and thus the putative infection risk cannot be underestimated; however the administration of the medication in a controlled ICU environment appears to be relatively safe.

The aforementioned concerns remain to be further clarified in upcoming TCZ randomized control trials [48, 49] . Recently, a therapeutic regime involving a course of high-dose methylprednisolone, followed by TCZ if needed, showed that it may accelerate respiratory recovery, reduce hospital mortality and the rate of invasive mechanical ventilation in COVID-19-associated cytokine storm syndrome [50] . Of note, the preliminary findings of a phase III global TCZ versus placebo study (EMPACTA) showed that the administration of TCZ in patients with COVID-19 associated pneumonia plus standard of care were 44% less likely to The prevalence of bacterial infections that were observed in the EMPACTA study was comparable with our present results.

Another point is that there is no consensus for the administration of TCZ in critically ill COVID-19 patients. Although a full panel of laboratory parameters was not available in this series, we found that most patients on admission had lymphocytopenia and increased levels of C-RP and Ddimers, indicating thus putative hyperinflammation [21] [22] [23] [24] [25] . This was a major study limitation as we did not establish a full blown cytokine storm [10, 11, 19] , and thus TCZ was administered mainly on clinical grounds and the rapid progression of COVID-19 pneumonia [21, 37, 38] .

Follow-up was also based on monitoring the evolution of the clinical picture, and thus the trend of possible changes in the laboratory parameters was not included in this study. Whether the occurrence of a cytokine release syndrome integrating elevated IL-6 levels should be a prerequisite for the administration of TCZ in COVID-19 patients remains to be fully elucidated in larger future studies. However, the presence of cytokine storm, which could facilitate the development of thromboinflammation and multi-system organ failure, could be a pivotal underlying mechanism in multifaceted COVID-19 critical illness [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] .

Notably, during the pandemic, many ICU beds and ventilators may not be available at all times as was the case in our study. In that sense, our preliminary results showed that a subset of COVID-19 patients had a fast (one to two weeks) and sustainable response to TCZ therapy, which consequently facilitated the extubation of several cases and their hospital discharge (Table   2 ). Moreover, the observed mortality rate remained within the range of previously published COVID-19 studies despite the fact that all enrolled patients were critically ill. However, the J o u r n a l P r e -p r o o f administration of TCZ per se as an adjunct therapy did not have any effect on mortality of COVID-19 patients, which duplicates a recently published trial [52] .

This retrospective case-series has several limitations, which prevent its generalizability. First, our patients might have improve to concomitant empiric antiviral and steroid therapy [4, 7-10, 30, 47, 50] . However, given the severity of their clinical status, the administration of TCZ might have helped by mitigating a full blown picture of hyperinfammation. Surely, the administration of steroids could have affected both the immune response and the viral clearance. The natural course of SARS-CoV-2's viremia is not well established, while reinfections and persistently positive RT-PCR results were reported [53] [54] [55] [56] . We are uncertain of the putative effect of TCZ on viral clearance although the RT-PCR results were negative in survivors post therapy. Surely, future studies should explore the indications and the optimal TCZ regime in COVID-19 critically ill patients [48] [49] [50] [51] [52] . In this study, the lack of a comparative control arm, the small number of enrolled patients, and the absence of a detailed laboratory documentation and follow-up rendered its power. Despite the aforementioned limitations, we showed that the administration of TCZ is a putative safe, adjunct therapy in COVID-19 critically ill patients.

The current results are preliminary and underpowered, and thus they should be interpreted accordingly. TCZ efficacy in severe COVID-19 needs to be validated by future randomized control trials. However, our data showed that that the administration of TCZ as an adjunct therapy could be an alternative management option in rapidly evolving COVID-19 pneumonia and associated critical illness.

The authors declare that they have no competing interests.

The study was approved by the Institutional Review Board of King Saud Medical City, Riyadh, Kingdom of Saudi Arabia [H-01-R-053, IORG#0010374, H1RI-11-20-02]. The study was also registered at http://www.researchregistry.com (number 6066: https://www.researchregistry.com/ browse-the-registry#home/registrationdetails/5f737013d347750015bc12d7/). Written informed consent to participate in this study was obtained from the patients (whenever possible) or their legal representatives.

Written informed consent was obtained from patients for publication of this case-series and accompanying images. Copies of the written consents are available for review by the Editor-in-Chief of this journal on request.

No funding was received for this study. More than one hospital acquired infection 3 (4.9%) 9 (14.7%) 0.01** Abbreviations: IQR = interquartile range, ICU = intensive care unit, APACHE 4 score = Acute physiology and chronic health evaluation 4 score *Comparisons with Wilcoxon rank sum test or student's t-test as appropriate; p values < 0.05 were statistically significant; ** Comparisons with Fisher's exact test or chi 2 test as appropriate, p values < 0.05 were statistically significant. 

Origin and evolution of pathogenic coronaviruses

WHO Middle East respiratory syndrome coronavirus (MERS-CoV) summary and literature update

China Medical Treatment Expert Group for Covid-19 Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

World Health Organization website

European Centre for Disease Prevention and Control website

COVID-19 Lombardy ICU Network. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study

COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and

Lung Injury in COVID-19-An Emerging Hypothesis

Comment on Hu et al: The cytokine storm and COVID-19

COVID-19 pathophysiology: A review

Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer

Thromboembolic findings in COVID-19 autopsies: pulmonary thrombosis or embolism?

Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans

Deep Vein Thrombosis in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: Prevalence, Risk Factors, and Outcome

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

COVID-19: consider cytokine storm syndromes and immunosuppression

CoV-2: a storm is raging

Tocilizumab for the treatment of severe coronavirus disease 2019

The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality

Cytokine release syndrome in severe COVID-19

Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?

Tocilizumab treatment in COVID-19: A single center experience

Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: Interim guidance

2019-nCoV) in suspected human cases. Interim guidance

Tocilizumab in patients with severe COVID-19: a retrospective cohort study

Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study

Covid-19 in Critically Ill Patients in the Seattle Region -Case Series

Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Association Between Hypoxemia and Mortality in Patients With COVID-19

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Clinical course and predictors of 60-day mortality in 239 critically ill patients with COVID-19: a multicenter retrospective study from Wuhan, China. Crit Care

Respiratory Mechanics of COVID-19-versus Non-COVID-19-associated Acute Respiratory Distress Syndrome

Tocilizumab for treatment of mechanically ventilated patients with COVID-19

A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial

Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial

Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study

BACC Bay Tocilizumab Trial Investigators. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

Positive RT-PCR Test Results in Patients Recovered From COVID-19

SARS-CoV-2 viral load in upper respiratory specimens of infected patients

A Case Series of Recurrent Viral RNA Positivity in Recovered COVID-19 Chinese Patients. Version 2

Recurrent Positive Reverse Transcriptase-Polymerase Chain Reaction Results for Coronavirus Disease 2019 in Patients Discharged From a Hospital in China

Highlights • Rapidly evolving respiratory failure is a hallmark of COVID-19-critical illness

• Tocilizumab could be an adjunct safe therapy in critically ill COVID-19 patients

• Tocilizumab did not affect the mortality of COVID-19 critically ill patients

• The prevalence of bacterial infections post-tocilizumab therapy was 19

Ahmed Mady: study design, data collection/analysis, writing the original manuscript. Waleed Aletreby: study design, data collection/analysis, writing the original manuscript

Alfateh Noor: study design, data collection/analysis, writing the original manuscript. Ibrahim Soliman: study design, data collection/analysis, writing the original manuscript

Dimitrios Karakitsos: data interpretation, supervision of the study, writing/editing the final version of the manuscript

data interpretation, supervision of the study, writing/editing the final version of the manuscript

Hyperlink to your specific registration

The authors wish to thank Ms. Katrina Baguisa, Ms. Huda Mhawish, Ms. Alva Alcazar, and Ms.Zahra Alfrdan for their help in collecting the data of this study.J o u r n a l P r e -p r o o f

J o u r n a l P r e -p r o o f

The following information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned. If you have nothing to declare in any of these categories then this should be stated.

All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.All authors declare no conflicts of interest.

All sources of funding should be declared as an acknowledgement at the end of the text. Authors should declare the role of study sponsors, if any, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. If the study sponsors had no such involvement, the authors should so state.No funding was received for this study.

Research studies involving patients require ethical approval. Please state whether approval has been given, name the relevant ethics committee and the state the reference number for their judgement. Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request".Patients have a right to privacy. Patients' and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions. Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.Written informed consent to participate in this study was obtained from the patients (whenever possible) or their legal representatives. Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Please specify the contribution of each author to the paper, e.g. study concept or design, data collection, data analysis or interpretation, writing the paper, others, who have contributed in other ways should be listed as contributors.

All authors reviewed the final version of the manuscript and agree with its submission to the journal.

In accordance with the Declaration of Helsinki 2013, all research involving human participants has to be registered in a publicly accessible database. Please enter the name of the registry and the unique identifying number (UIN) of your study.

The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish Dr. Dimitrios Karakitsos Dr. Dimitrios Karakitsos, Critical Care Dept., King Saud Medical City, Work address: PO Box 331905, Zip code: 11373 -Shemaisi, Riyadh, Saudi Arabia, email: karakitsosdimitrios@gmail.com, phone: +966-509816296.